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Abstract
Hypoxic pulmonary hypertension (HPH) is initially a disease of the small pulmonary arteries. Its severity is usually
quantified by pulmonary vascular resistance (PVR). Acute Rho kinase inhibition has been found to reduce PVR
toward control values in animal models, suggesting that persistent pulmonary vasoconstriction is the dominant
mechanism for increased PVR. However, HPH may also cause proximal arterial changes, which are relevant to
right ventricular (RV) afterload. RV afterload can be quantified by pulmonary vascular impedance, which is
obtained via spectral analysis of pulsatile pressure-flow relationships. To determine the effects of HPH
independent of persistent pulmonary vasoconstriction in proximal and distal arteries, we quantified pulsatile
pressure-flow relationships before and after acute Rho kinase inhibition and measured pulmonary arterial
structure with microcomputed tomography. In control lungs, Rho kinase inhibition decreased 0 Hz impedance
(Z0), which is equivalent to PVR, from 2.1 ± 0.4 to 1.5 ± 0.2 mmHg·min·ml−1 (P < 0.05) and tended to increase
characteristic impedance (ZC) from 0.21 ± 0.01 to 0.22 ± 0.01 mmHg·min·ml−1. In HPH lungs, Rho kinase inhibition
decreased Z0 (P < 0.05) without affecting ZC. Microcomputed tomography measurements performed on lungs
after acute Rho kinase inhibition demonstrated that HPH significantly decreased the unstressed diameter of the
main pulmonary artery (760 ± 60 vs. 650 ± 80 μm; P < 0.05), decreased right pulmonary artery compliance, and
reduced the frequency of arteries of diameter 50–100 μm (both P < 0.05). These results demonstrate that acute
Rho kinase inhibition reverses many but not all HPH-induced changes in distal pulmonary arteries but does not
affect HPH-induced changes in the conduit arteries that impact RV afterload.
pulmonary arterial hypertension is clinically defined as a mean pulmonary arterial pressure (mPAP) >25 mmHg
at rest with a pulmonary arterial wedge pressure <15 mmHg (34). While mPAP and a single-point pulmonary
vascular resistance calculation (mPAP divided by cardiac output) are the most common metrics of hypertension
severity (41), neither is a measure of the pulsatile work required by the right ventricle (RV) to cyclically pump
blood to the pulmonary vasculature. Furthermore, increased mPAP alone is not enough to cause RV failure (3). A
more effective measure of total RV afterload is the pulmonary vascular impedance (PVZ), which depends on
both proximal compliance and distal resistance and is calculated from pulsatile pressure-flow relationships. The
clinical importance of proximal compliance has been increasingly recognized (6, 14, 32). Additionally, decreased
main pulmonary artery compliance is an excellent predictor of mortality in pulmonary arterial hypertension
(14, 32). Therefore, it is important to understand both the proximal and the distal arterial effects of drugs used
to treat pulmonary arterial hypertension.
Many drugs efficacious for the treatment of severe pulmonary hypertension do not decrease mPAP or resistance
as much as expected given the resulting increases in patient exercise capacity and decreasing mortality (5, 13). It
has been speculated that these drugs function by direct action on the RV (i.e., by increasing contractility) and/or
by decreasing the pulsatile hydraulic load (61), which depends on proximal compliance (14, 32). An exception is
the Rho kinase inhibitor fasudil, which has been found to modestly reduce pulmonary vascular resistance in
patients with severe pulmonary hypertension (11), secondary pulmonary hypertension (30), and idiopathic
pulmonary hypertension (21). In experimental animals, acute Rho kinase inhibition has been shown to nearly
eliminate increases in pulmonary artery pressure induced by chronic hypoxia (19, 43) and is a major contributor
to pulmonary hypertension in monocrotaline-injected rats (18, 42) as well as those treated with the vascular
endothelial growth factor receptor blocker SUGEN-5416 (46); see Ref. 35 for a comprehensive review.
Nevertheless, the effects of Rho kinase inhibition on proximal compliance and pulsatile pressure-flow
relationships in the lung remain unknown.
We have previously reported on the utility of the isolated, ventilated, perfused lung system for measuring
pulsatile pressure-flow relationships independent of changes in sympathetic nervous system tone, anesthesia,
and volume status (60), which cannot be avoided in intact animal preparations. In addition, we have used
microcomputed tomography to quantify the changes in proximal and distal arterial morphometry and

mechanics that occur with chronic hypoxia-induced hypertension in rats (39). Here, we combine these
techniques to determine the effects of acute Rho kinase inhibition on chronic hypoxia-induced changes in RV
afterload and proximal and distal pulmonary artery morphometry and mechanics in mice. Given the frequent
and increasing use of genetically engineered mice to understand the molecular mechanisms of human disease,
techniques appropriate for mouse lungs such as these are vital. We hypothesized that acute Rho kinase
inhibition would eliminate persistent distal vasoconstriction, thereby normalizing mPAP and pulmonary vascular
resistance, but that proximal arterial stiffening—and subsequent changes in PVZ—would persist.

METHODS
Animal handling.
Twenty-four male 10- to 12-wk-old C57BL6/J mice, 25.8 ± 2.3 g body wt, were used (Jackson Laboratory, Bar
Harbor, ME). Mice were exposed at the University of Wisconsin-Madison Biotron facility to zero [control
(CTL): n = 14] or 10 days [hypoxic pulmonary hypertension (HPH): n = 10] of hypobaric hypoxia such that the
partial pressure of O2 was reduced by half, as previously described (58). Mice were then used for either pulsatile
pressure-flow studies (CTL: n = 6, HPH: n = 5) or microcomputed tomography imaging studies (CTL: n = 8,
HPH, n = 5). For the former, mice were anesthetized with an intraperitoneal injection of 150 mg/kg body wt
pentobarbital sodium which has been shown not to affect pulmonary hemodynamics (2, 29, 33). For the latter,
mice were anesthetized with 52 mg/kg body wt pentobarbital sodium and then euthanized by exsanguination. In
both cases, while the heart was still beating, heparin sodium (200 IU in 0.2 ml) was injected into the RV to
prevent blood clotting in the lungs. All protocols and procedures were approved by the University of Wisconsin
and Zablocki VA Medical Center Institutional Animal Care and Use Committees.

Pulsatile pressure-flow studies.
The isolated, ventilated, perfused mouse lung preparation was used for pulsatile pressure-flow studies as
previously developed and validated (58, 59) (Fig. 1). In brief, following euthanasia, the trachea, pulmonary
artery, and left atrium were cannulated for ventilation, perfusate inflow, and perfusate outflow, respectively.
The tracheal cannula was inserted approximately halfway into the trachea. The pulmonary artery cannula was
positioned in main pulmonary artery with the tip just proximal to the first bifurcation. The left atrial cannula was
inserted through the mitral valve and then withdrawn until the flares of the tip base abutted the valve annulus.
The lungs were ventilated with room air and perfused with heated RPMI 1640 cell culture medium with 3.5%
Ficoll (an oncotic agent). A syringe pump (Cole-Parmer, Vernon Hills, IL) was used to create steady pulmonary
vascular flow of perfusate, and a high-frequency oscillatory pump (Bose-Electro Force, Eden Prairie, MN) was
used in parallel with the syringe pump to superimpose a oscillatory component on the pulmonary vascular flow.
Pressure transducers (P75, Harvard Apparatus, Holliston, MA) measured the instantaneous pulmonary artery
pressure (PAP) and left atrial pressure (LAP). Instantaneous flow rate (Q) was measured with an in-line flow
meter (Transonic Systems, Ithaca, NY). Pressures and flows were monitored by continuous display on a laptop
computer and recorded at 200 Hz.

Fig. 1.Schematic of isolated lung setup showing the inlets for steady and oscillatory flow and the sites for
measurement of instantaneous pulmonary artery flow rate Q (flow sensor), pulmonary artery pressure (PA
pressure sensor), and left atrial pressure (LA pressure sensor).
The pulsatile flow rate measurements were performed according to established methods after initial steady
pressure-flow measurements of PAP, LAP, and Q at 1 ml/min (58, 59). In particular, pulsatile pressure-flow data
were recorded for flow rates of the form Q = 3 + 2 sin (2πft) ml/min at frequencies (f) = 1, 2, 5, 10, 15, and 20 Hz.
At the higher frequencies (15 and 20 Hz), the imposed waveforms were not ideal (1–5 ml/min); maxima
(minima) were less (greater) than desired. Nevertheless, the imposed waveforms were not significantly different
between control and hypoxic lungs. Above 20 Hz, which is ∼2.5 times the heart rate for mice, ∼8 Hz in conscious
unrestrained mice (52), the deviation from the desired waveform was too high to provide good signal-to-noise
ratios in the resulting pressure data. Between protocols, the lungs were allowed to rest for 1 min with normal
ventilation (2 to 10 cmH2O at 90 breaths/min) (62) and a steady flow rate of Q = 0.5 ml/min. All data were
recorded with the lungs inflated at the end-inspiratory pressure of 10 cmH2O. In preliminary studies, we
observed that lower airway pressures yielded lower PAP values, in a mildly flow-dependent manner. However,
we did not observe dramatic differences in this flow dependence between CTL and HPH lungs.
Following measurements in the baseline smooth muscle cell (SMC) tone state, a Rho kinase inhibitor (Y27632;
Sigma Chemical, St. Louis, MO) was added to the perfusate to a final concentration of 10−5 M to induce a
vasodilated state. This concentration was selected on the basis of a literature review of isolated mouse (10) and
rat (19, 43) lung studies in which this dose maximally decreased mPAP while still selectively inhibiting Rho kinase
(22). Pulsatile pressure-flow measurements were taken 15 min after Y27632 administration, followed by steady
flow rate measurements. This time point was chosen to allow the effect of Y27632 to stabilize per prior reports
(42, 43).

Calculations for pulsatile pressure-flow studies.
Pulmonary vascular impedance magnitude (Z) and phase (Θ) were calculated from one full sinusoidal cycle of ΔP
= PAP − LAP and Q at each frequency tested (f = 1, 2, 5, 10, 15, and 20 Hz). Input impedance Z0 was calculated by
averaging the impedance at the 0th harmonic (f = 0 Hz) from all tested frequencies. Characteristic impedance
ZC was calculated as the average of Z values between the first minimum (5 Hz) and the highest frequency
imposed (20 Hz) and index of wave reflection RW was calculated as (Z0 − ZC)/(Z0 + ZC) (44).

Theoretical ZC-mPAP and RW-mPAP relationships.
If viscous effects in the artery wall and at the blood-artery interface are neglected, ZC corresponds to the square
root of the inertance divided by the compliance of the proximal segments of the arterial network (38).
Alternatively, under similar assumptions, ZC can be calculated as the product of fluid density and pulse wave
velocity divided by the luminal cross-sectional area of the proximal arteries (63). Both approaches reduce to
𝜌𝐸ℎ
ZC = √ 2 5
2𝜋 𝑟
where E, r, and h are proximal artery elastic modulus, luminal radius, and wall thickness, respectively, and ρ is
density of blood.
To predict the dependencies of ZC and RW on mPAP, we used a theoretical approach, outlined in the appendix.
Essentially, the characteristic impedance depends on E, r, and h where r and h are a function of initial radius and
wall thickness (r0 and h0, respectively) as well as the mean transmural pressure mPAP. With increasing mPAP,
the artery distends such that r increases and h decreases by conservation of mass for a fixed artery length. For a
particular set of E, r0, and h0 values, ZC as a function of mPAP can be found exactly (see appendix).
We used an iterative approach to find the combinations of E, r0, and h0 that yielded a theoretical ZC-mPAP
relationship that best fit the experimental data. No unique combination of E, r0, and h0 was found to minimize
error for either the CTL or the HPH data in the baseline SMC tone state or as combined with data in the dilated
(with Y27632) state. Therefore, sets of E, r0, and h0 values for which the sum of the squared error between
experimental and theoretical ZC was <0.0015 were considered potential solutions. No differences in the
potential solution space were found for CTL vs. CTL + Y27632 or for HPH vs. HPH + Y27632. Therefore, extrema
of the resulting solution spaces (i.e., parameter sets of E, r0, and h0 for best fit to CTL + Y27632 and HPH +
Y27632 with maximum and minimum r0 values) were plotted against experimental data. R2 values and P values
were found for the resulting theoretical ZC values in relation to the experimental ZC values. Theoretical RW values
and RW-mPAP relationships were calculated at these same extrema of the solution space (i.e., parameter sets
of E, r0, and h0) based on the definition of RW = (Z0 − ZC)/(Z0 + ZC), where Z0 = Q × mPAP + LAP.

Microcomputed tomography imaging studies.
Preparation of mouse lungs for microcomputed tomography was modified from methods previously used on
rats (25). Briefly, the pulmonary artery and trachea were cannulated (PE-90 tubing, 1.27 mm outer diameter and
0.86 mm inner diameter) and the heart was dissected away. The pulmonary artery cannula was positioned in
main pulmonary artery well above the first bifurcation. The lungs were ventilated with 15% O2-6% CO2, balance
nitrogen, at 90 breaths/min with 4 cmH2O end-expiratory pressure and 10 cmH2O end-inspiratory pressure. The
lung was rinsed free of blood with a physiological salt solution containing 5% bovine serum albumin, and
hemodynamic measurements were taken at flow rates in the range of 0–3 ml/min. The Rho kinase inhibitor
Y27632 was administered (10−5 M) to dilate the pulmonary vasculature before imaging. The perfusate with
Y27632 was allowed to recirculate for 5 min before steady flow rate measurements were retaken.
Following steady flow rate measurements, the cannulas were clamped at end-inspiration and the isolated lungs
were placed in the imaging chamber as previously described (25). The lungs were ventilated with the same gas
mixture; the perfusate was replaced with perfluorooctyl bromide (PFOB). This vascular contrast agent was
selected because perfluorochemicals, which are a good alternative to traditional artificial blood substitutes (20),
have been shown to inhibit vasoactivity (49). The lungs were conditioned by cycling the intravascular pressure
from 0 to 25 mmHg briefly several times. Then, the arterial pressure was set to 7.4 mmHg, and the lungs were
rotated in the X-ray beam at 1° increments to obtain 360 planar images. The pressure was lowered to 6.3 mmHg

and then raised to 13.0 and 17.2 mmHg with complete computed tomography scans at each pressure as
previously described (24).
Briefly, the microfocal X-ray computed tomography system is composed of a Fein-Focus-100.50 X-ray source (3μm focal spot) and a North American Imaging AI-5830-HP image intensifier coupled to a Silicon Mountain Design
charge-coupled device (CCD) camera. To minimize noise as well as maximize vascular contrast, each planar
projection image is a result of averaging seven frames. The image data are transmitted from the CCD camera to
a computer. Image acquisition, positional information recording, and stage control are all preformed by inhouse, custom-written, Windows-based software running on the workstation. Between each scan, the
intravascular pressure was briefly raised to ∼25 mmHg and then lowered to each value set for image acquisition.
While we attempted to keep the geometry similar from scan to scan, it varied slightly depending on lung size,
mostly height. The spatial resolution of a typical volumetric mouse lung scan was between 30 and 40 μm. Highresolution planar images were also captured at each of the four pressures in a randomly selected section in the
peripheral parenchyma of each lung. The resolution of these images was in the range of 6 to 8 μm.
The order of pressures was determined from preliminary studies to minimize vascular leakage at higher
pressures. Intravascular pressures were maintained hydrostatically and calculated as the difference between the
level of PFOB in the reservoir and the center of the lung, taking into account the density of the PFOB. With this
technique, only the contrast-filled luminal volumes are detectable, not the walls themselves. As a consequence,
direct measurements of wall thickness throughout the lung and as a function of pressure were not possible.
After each mouse lung was imaged at all four pressures, a flood field image (lung removed from the beam) and a
BB field image (a phantom of a uniform grid of 1-mm diameter stainless steel spheres spaced at 1.5-cm
intervals) were taken to be used in the correction for spatial variations and correction for spatial distortion,
image intensifier gain, and beam geometry.

Measurements from microcomputed tomography imaging studies.
Images of the contrast-filled luminal volumes were preprocessed to correct image intensifier spatial distortion
and nonuniform illumination intensity. The 360 planar images were then reconstructed into an isometric threedimensional (3-D) volume using a Feldkamp cone-beam algorithm.
The reconstructed images were converted to Dicom 3.0 (497 × 497 × 497 pixels) and then imported into the
commercially available software package Mimics (Materialise, Leuven, Belgium). Following segmentation, a 3D
surface mask of the whole arterial tree was generated (Fig. 2A). The right principal pathway was then isolated
using 3-D editing by following the path of the largest diameter branch at each bifurcation (Fig. 2B). Using the
medCAD package in Mimics, which has previously been used to quantify the anatomy and branching
morphometry of the abdominal aorta (7, 45), the centerline coordinates and best fit arterial luminal diameter
for sections perpendicular to the centerline were generated at a point spacing of 1 pixel along the pathway. The
centerline coordinates and corresponding luminal diameters were imported into Matlab (MathWorks, Natick,
MA) for postprocessing data reduction. Each segment of the principal pathway was characterized by a distance
from the origin (located at the end of the cannula) and a diameter, and dimensions were converted using the
luminal diameter of the cannula for calibration (Fig. 2C). The length of each segment was calculated as the
distance between the postbifurcation points. Measurements were made on arteries ranging in size from 1,200
to ∼80 μm in diameter. On the basis of an assumed error in the centerline coordinates and diameter fits from
Mimics of 1 pixel, the average percent error in the length measurement was found to be approximately 2.5%
and 12% for the longest and shortest vessels, respectively; error in the diameter measurement was about 4%
and 18% for the largest and smallest vessels, respectively. The absolute measurement errors were less than the
standard deviations of the diameter and length in CTL and HPH groups.

Fig. 2.A: planar images were reconstructed into three-dimensional (3-D) volumes and imported into Mimics. B: a
3-D surface mask was generated from which the right principal pathway was isolated. Using the medCAD
package in Mimics, the centerline coordinates and best fit diameters were found for the principal pathway. C:
from all of the diameter measurements, the data were reduced to the diameter of each branch by finding the
midsegment diameter. Representative measurements are shown of the midbranch diameter for the first
segment (mid 1) and the 10th segment (mid 10) as well as the pulmonary artery cannula (Cannula) at a lower
pressure (dashed gray line) and a higher pressure (solid gray line).

Calculations for microcomputed tomography imaging studies.
The distensibilities of the intralobar and extralobar arteries were calculated from multiple measurements made
in the same lung at different intravascular pressures at identical locations in the principal pathway (Fig. 2C). The
pressure in individual segments was calculated on the basis of the height difference with respect to the center of
the lung (the hydrostatic gradient reference point). A morphometric model (39) was applied to the arterial
diameters as a function of distance from the main trunk inlet (x) and pressure (P) to calculate distensibility of the
principal pathway (αlung) from the following equation: D(x,P) = D(0,0) (1 + αlung P)(1 − x/Ltot)c, where D(0,0) is the
unstressed diameter of the main pulmonary artery (x = 0), Ltot is the total length of the principal pathway,
and c is a measure of the taper of the principal pathway. Using the relationship between the cumulative number
of branches (NBR) and the distance along the main trunk (Ltot), an estimate of the total number of branches off
the main trunk (Ntot) was calculated from: NBR(x) = Ntot[1 − (1 − x/Ltot)]b, where b is a measure of the branch
distribution along the principal pathway. For the extralobar right pulmonary artery (RPA), we quantified
distensibility (αRPA) using the linear pressure vs. diameter relationship proposed by Yen et al. (64) and used by
Molten et al. (39): αRPA = β/D(x,0), where β = (D(x,P) − D(x,0))/P. Compliance of the RPA (CRPA) was calculated as
αRPA times the luminal cross-sectional area of the unstressed RPA (63).
Structural changes in the distal vasculature (arteries with diameters <150 μm) were quantified from highmagnification planar images of mouse pulmonary arteries. The diameter of each artery in a 2 × 2 mm square
containing one terminal branch was measured by an observer blinded to experimental conditions. Lungs for
which images had overlapping terminal branches or incomplete branches were excluded. In each lung the
frequency of arteries in the size ranges 20–50 μm, 50–100 μm, and 100–150 μm were counted at each pressure.

Statistical analysis.
Absolute changes in study endpoints with regard to state (baseline SMC tone vs. dilated with Y27632) and
exposure (CTL vs. HPH) were analyzed using a generalized least squares (GLS) for repeated measures with an
unstructured variance-covariance structure. The three-way comparison of factors (state, exposure, and
frequency) was significant, which led to the construction of contrast matrices to investigate changes in Z due to
state and exposure as a function of frequency. GLS models with two-way comparisons (state and exposure)

were constructed to analyze changes in study endpoints mPAP, Z0, ZC, and RW. If there was a significant
interaction of factors, contrast matrices were constructed to investigate changes in endpoints as a function of
state.
To investigate changes in the frequency of distal arteries, a GLS model with two-way comparison of factors
(exposure and pressure) was used. Structural data endpoints (Ltot, NBR, αlung, D(0,0), αRPA, CRPA, RPA length) were
analyzed by one-way analysis of variance to analyze differences between control and hypoxic lungs. No
violations of the normality assumption were found, and P < 0.05 was considered significant. All P values were
two-sided, and all statistical analyses were performed using R software (http://www.R-project.org/, version
2.5.1). All data are presented in terms of means ± SD.

RESULTS
In both control and hypoxic lungs, Y27632 decreased PAP (Fig. 3). In the Y27632 state with a steady flow of 3
ml/min, chronic hypoxic lungs continued to have elevated pressures when compared with control lungs. This
persistent effect of chronic hypoxia in the presence of acute Rho kinase inhibition was investigated using highmagnification images of the terminal branches. Qualitatively, fewer small arteries were detectable in HPH lungs
compared with CTL lungs (Fig. 4, B vs. A). Quantitatively, hypoxic and control lungs had the same number of
measured arteries 100–150 μm; however, hypoxia caused functional rarefaction of the arteries 50–100 μm in
diameter even with acute Rho kinase inhibition (Fig. 4C). Also, there was a significant increase in number of
arteries 50–100 μm in diameter measured at 17 mmHg in the CTL lungs but there was no change in HPH lungs.
The frequency of the smallest visible arteries, 20–50 μm, tended to decrease with increased vascular pressure,
but the change was not significant.

Fig. 3.Mean pulmonary arterial pressure (mPAP) at 3 ml/min for control (CTL; n = 6) and hypoxic pulmonary
hypertension (HPH; n = 5) mouse lungs in the baseline smooth muscle cell (SMC) tone state and with Y27632.
*P < 0.05 vs. 0-day; †P < 0.05 Y27632 vs. baseline.

Fig. 4.A and B: high-magnification planar images of terminal branches of pulmonary arteries in CTL (n = 5; A) and
HPH (n = 5; B) mouse lungs. Bar length is 500 μm. C: frequency of arteries, 20–50, 50–100, and 100–150 μm in
diameter, in CTL and HPH lungs as a function of pressure. All lungs were perfused with Y27632 before imaging.
Qualitatively and quantitatively, the HPH lungs have fewer visible distal branches than CTL lungs. *P < 0.05 vs.
CTL. #P < 0.05 vs. 6.3 mmHg.
To determine the ability of acute Rho kinase inhibition to reduce or eliminate chronic hypoxia-induced changes
in RV afterload, pulsatile pressure-flow relationships in CTL and HPH lungs with and without perfusion with
Y27632 were analyzed. All impedance spectra had the expected “L”-shape with a high amplitude at zero
frequency and a rapid decline to low amplitudes at higher frequencies with moderate oscillations; the phase
angles were negative at low frequencies and approached zero at higher frequencies (Fig. 5). In control lungs (Fig.
5A), Y27632 decreased Z0 and shifted the ratio of pressure to flow moduli to higher pressures at high
frequencies. As a consequence, Y27632 tended to increase ZC; the increase in ZC combined with the decreased
Z0 led to a decrease in Rw (Table 1). Phase angle was unaffected. In hypoxic lungs (Fig. 5B), Y27632 decreased
Z0 and had no effect on the ratio of pressure to flow moduli at high frequencies, resulting in no change of ZC.
Here, the decrease in Z0 relative to ZC resulted in a decrease in RW.

Fig. 5.Pulmonary vascular impedance magnitude (Z) and phase (θ) spectra in isolated perfused lungs from CTL
(n = 6; A) and HPH (n = 5; B) mouse lungs in a baseline SMC tone state and with Y27632 and from CTL and HPH
mouse lungs with Y27632 (C). *P < 0.05 vs. 0-day; †P < 0.05, for change from baseline to Y27632.
Table 1. Metrics of impedance (Z0, ZC, RW) for CTL (n = 6) and HPH (n = 5) mouse lungs in the baseline SMC tone
state and with Y27632
Z0, mmHg · min ·
ml−1
CTL

ZC, mmHg ·
min · ml−1

RW (dimensi
onless)

HPH

CTL

HPH

CTL

HPH

Baseline 2.1 ± 0.4

4.0 ± 0.7*

0.21 ± 0.01

0.194 ± 0.009

0.81 ± 0.05

0.91 ± 0.01*

Y27632

2.2 ± 0.2*†

0.22 ± 0.01

0.187 ± 0.005*

0.73 ± 0.03†

0.84 ± 0.02*†

1.5 ± 0.2†

Values are means ± SD. Z0, 0-Hz impedance; ZC, characteristic impedance; RW, wave reflection; CTL, control;
HPH, hypoxic pulmonary hypertension; SMC, smooth muscle cell.
*P < 0.05 vs. CTL;
†P < 0.05, for change from baseline to Y27632.

Either with or without Rho kinase inhibition, chronic hypoxia increased Z0 and decreased the magnitude at
higher frequencies, resulting in a crossover between the two PVZ spectra. Hypoxia tended to affect phase angle,
but no significant effect as a function of frequency was found (Fig. 5C; with Y27632 shown only).
The contribution of proximal arterial size and compliance to pulsatile pressure-flow measurements in the
isolated lungs was investigated using the theoretical relationships between the impedance metrics
ZC and RW and mPAP. Theoretical ZC was calculated for proximal artery elastic modulus, E, from 60 to 250 kPa;
wall thickness, h0, from 60 to 250 μm; and luminal diameter, D0 = 2r0 from 800 to 2,000 μm. The combinations
of E, h0, and D0 that were considered solution spaces had a total squared sum of error <0.0015. In CTL lungs, the
baseline and Y27632 states were well described by a proximal artery elastic modulus E in the range of 100 to
240 kPa, wall thickness h between 25 and 50 μm, and inner diameter of 1,010 to 1,160 μm (Fig. 6 solid lines:
bounding fits; R2 = 0.51; P < 0.01). The HPH lungs could be described by E = 235–250 kPa, h = 120–200 μm, and
inner diameter = 1,690–1,940 μm (Fig. 6, dashed lines: bounding fits; R2=0.057; P = 0.5).

Fig. 6.Characteristic impedance (ZC) as a function of mPAP for CTL (n = 6; □ and ■) and HPH (n = 5; ▴ and ▵)
mouse lungs in a baseline SMC tone state and with Y27632 (white). The extrema of the solution spaces for the
theoretical ZC-mPAP relationships are shown by the bounding areas for CTL (solid lines) and HPH (dashed lines).
Sum of squared error (SSE) for each model fit to experimental data is shown.
Like ZC, RW exhibited a marked dependency on mean PAP (Fig. 7). For the solution spaces for a good fit of
theoretical ZC-mPAP relationship to experimental data in CTL and HPH lungs given above, RW as a function of
mPAP was calculated. The resulting curvilinear relationships fit the experimental results for CTL and HPH
conditions well (CTL: R2 = 0.97; P < 0.001, HPH: R2 = 0.99; P < 0.001).

Fig. 7.Index of wave reflection (RW) as a function of mPAP for CTL (n = 6; □ and ■) and HPH (n = 5; ▴ and ▵)
mouse lungs in a baseline SMC tone state and with Y27632 (white). Overall, Y27632 decreased mPAP but did not
shift the RW-mPAP relationship. The extrema of the solution spaces for the theoretical RW-mPAP relationship are
shown by the bounding areas for CTL (solid lines) and HPH (dashed lines).
Despite these significant differences in PVZ metrics between CTL + Y27632 and HPH + Y27632, few differences
were evident in the imaging analysis of whole mouse lungs. In particular, total length (Ltot), number of branches,
αRPA and αlung and length were not different (Table 2). Only the extrapolated zero pressure diameter of the main
pulmonary artery (D(0,0)) and CRPA were significantly affected by HPH after acute Rho kinase inhibition (Table 2;
both P < 0.05).
Table 2. Structural parameters of the mouse pulmonary vasculature measured from micro-CT images of isolated
mouse lungs with Y27632
Parameter
CTL
HPH
P Value
Ltot, mm
18.7 ± 0.9
18.0 ± 0.7
0.14
NBR
28 ± 4
25 ± 5
0.19
αlung, %/mmHg
2.3 ± 0.8
2.7 ± 1.0
0.52
D(0,0), μm
760 ± 60
650 ± 80*
0.02
αRPA, %/mmHg
2.5 ± 1.1
1.9 ± 0.6
0.26
2
CRPA, mm /mmHg 0.011 ± 0.004 0.006 ± 0.002* 0.04
RPA length, mm
2.9 ± 0.3
3.1 ± 0.3
0.27
RPA diameter, μm 740 ± 60
740 ± 50
0.93
Values are means ± SD. CT, computed tomography; Ltot, total length; NBR, number of branches; αlung, whole
lung distensibility; D(0,0), unstressed diameter of main pulmonary artery; αRPA, right pulmonary artery
distensibility; CRPA, RPA compliance.
*P < 0.05 vs. CTL.

DISCUSSION
The main findings of the present study are that acute Rho kinase inhibition nearly normalizes increases in mPAP
and pulmonary vascular resistance caused by chronic hypoxia but that proximal arterial thickening and stiffening
persist. Stiffening was evident in proximal arteries from imaging studies at controlled pressures (CRPA) as well as
from pulsatile pressure-flow relationships (ZC-mPAP relationship); thickening was evident from the analysis of

pressure-flow relationships. Interestingly, despite the nearly normalized mPAP and Z0, acute Rho kinase
inhibition did not eliminate chronic hypoxia-induced apparent pruning of small pulmonary arteries 50 to 100 μm
in diameter. This finding refutes the hypothesis proposed by some (55) that apparent pruning is due to
persistent pulmonary vasoconstriction and not structural remodeling.
Recent studies in mice and rats have found that persistent vasoconstriction mediated by Rho kinase activation is
a major contributor to increased pulmonary vascular resistance caused by HPH (10, 19, 35, 43). In vivo, chronic
administration of Y27632 decreased RV systolic pressure by 10% in the lungs of mice exposed to HPH (10) and
acute administration of Y27632 decreased RV peak systolic pressures in the lungs of rats exposed to HPH by 35%
(19) and 20% (43). Similar decreases were found ex vivo in isolated rat lungs; administration of 10−6 M Y27632
decreased PAP by 15% (19, 43). A 10-times higher concentration decreased PAP by 30% in HPH lungs and 20% in
CTL lungs of rats (43). In our isolated mouse lungs, the effect of Y27632 at 3 ml/min was less; a concentration of
10−5 M Y27632 decreased PAP by 20% in HPH lungs and 10% in CTL lungs. At a typical isolated perfused lung flow
rate of 1 ml/min, it was comparable; Y27632 decreased PAP by 30% in HPH lungs and 20% in CTL lungs. Thus,
our results confirm that the predominant mechanism of increased pulmonary vascular resistance with exposure
to hypoxia on the order of weeks is persistent pulmonary vasoconstriction in resistance arteries; i.e., reactive
changes in distal arteries.
The mechanisms of changes in conduit arteries appear different. In large arteries, we and others have found that
reactive changes are minimal, whereas fixed changes are significant. That is, previous direct measurements of
arterial deformation with increasing pressure have demonstrated that HPH decreases the compliance of
extralobar pulmonary arteries in passive and Rho kinase-inhibited states (27, 56); i.e., HPH causes proximal
artery stiffening as found here (CRPA; Table 2). Our impedance-derived estimates of proximal segment elastic
modulus and wall thickness changes with HPH support fixed changes in proximal arteries that lead to increased
stiffness. We have postulated that increased arterial wall strain due to hypertension stimulates smooth muscle
cells to increase collagen production as a way of normalizing circumferential stress and strain (27, 56); others
have suggested that the adventitial fibroblast response to hypoxia via p38 mitogen-activated protein kinase
(1, 40), transcription of hypoxia-inducible factor-1α (54), and the expression of early growth response-1 (15) is
responsible for increased collagen and other extracellular matrix components (12, 47). We note, however, that
species-dependent differences have been identified in mechanisms of HPH-induced proximal artery remodeling.
In particular, adventitial cells appear to play a larger role in large animals whereas medial cells play a larger role
in smaller animals, including rodents (53).
Some fixed changes in resistance arteries were found here, via microcomputed tomography imaging and Rho
kinase inhibition-resistant increases in mPAP and Z0. We interpret the imaging results as “apparent pruning”
because we speculate that there is not an actual loss of small arteries as previously suggested (17, 36, 37, 48),
but instead a functional narrowing that prohibits PFOB contrast infusion and thus optical detection. The
frequency of vessels 20–50 μm tended to decrease with increased pressure, suggesting that as pressure
increased, the vessels distended, resulting in an increase in frequency of vessels 50–100 μm. Confirmation of
this suggestion must await development of higher-resolution imaging modalities or different contrast agents
that allow detection of artery diameters continuously from 50–100 μm in diameter down to the capillary level.
Previously, we have demonstrated increased collagen-related gene expression in lung tissue of mice exposed to
hypoxia (9); even in these small resistance arteries we postulate that increased arterial wall strain stimulates
smooth muscle cells to increase collagen production to normalize circumferential stress and strain.
We calculated whole lung distensibility, αlung to further assess fixed changes in the lung vasculature, but this did
not decrease with HPH (Table 2). The sensitivity of this parameter to HPH-induced pulmonary vascular
remodeling is unclear. While it incorporates proximal and distal arterial mechanics, it is more sensitive to distal
arterial mechanics than proximal arterial mechanics (31). The lack of significant changes in αlung may be due to

the relatively short duration of hypoxia (10 days). We predict that as duration of chronic hypoxia increases, the
proportion of fixed to reactive changes in the lung increases, at least up to some point of stabilization. Prior
work from our group has found no significant differences in proximal arterial mechanics, pulmonary vascular
resistance or pulmonary vascular impedance between 10 and 15 days of hypoxia exposure (27, 58), but those
studies did not explore fixed vs. reactive changes. As shown here, 10 days of hypoxia was sufficient to induce
significant reactive and some fixed changes in distal arteries and fixed but not reactive changes in the proximal
arteries. The latter finding is supported by our recent work on the effects of vasoactivity and HPH on extralobar
pulmonary artery biomechanics (56).
Our results are inconsistent on the effect of HPH on extralobar artery size. Direct measurements of RPA
diameter show no change with HPH, but the whole lung pulmonary arterial luminal surface fitting approach to
find D(0,0) demonstrates a decrease (Table 2). Direct measurements in isolated extralobar arteries have shown
that HPH does not alter diameter at low pressures (27, 56). Moreover, the impedance-derived proximal segment
diameter estimates suggest that HPH increases proximal artery diameter. We speculate that the whole lung
morphometry surface fitting underestimates D(0,0) in HPH lungs because of sensitivity to the distal arteries and
that, in fact, no change occurs. Also, the impedance-derived proximal artery diameter estimates are for an
idealized “effectively proximal” artery that includes extralobar and intralobar arteries, and may include some
intermediate arteries. This is consistent with findings in rats where the first generation branch was found to be
larger in chronically hypoxic lungs than control lungs (51). The impedance-derived proximal artery wall
thickening finding cannot be confirmed by microcomputed tomography since only the contrast-filled regions are
visible, but it is supported by prior isolated vessel experiments (27, 56). Interestingly, the overall findings of the
impedance-derived structural analysis—that HPH increases proximal artery elastic modulus, wall thickness, and
luminal diameter—are supported by prior studies (27, 56) despite a poor fit of the theoretical model to the
experimental data in this condition (R2 = 0.057; Fig. 6). The increase in RW with HPH, which could cause wave
reflections to return earlier, may weaken the assumption that the high-frequency components of PVZ are
reflection free. Alternatively, HPH may be associated with changes in the proximal arteries not captured in the
simple model we propose here. Further work is needed to develop a more sophisticated model of proximal
arterial mechanics that would provide additional, useful insights into pulmonary hemodynamics and changes
with HPH.
We have previously shown that HPH decreases characteristic impedance and increases wave reflections (58) and
that the ZC-mPAP relationship provides insight into the effects of vasoactive agents and hypoxia on the proximal
and distal vasculature (60). Here we show that acute Rho kinase inhibition does not eliminate these effects of
HPH on RV afterload; the same functional differences in pulsatile pressure-flow relationships persist with acute
Rho kinase inhibition. In addition, we were able to demonstrate structural changes induced by chronic hypoxia
that account for these functional changes. In particular, we found decreased compliance (i.e., stiffening) of the
right main extralobar artery by microcomputed tomography with few other changes to whole lung
morphometry, findings that are supported by our theoretical analysis of ZC-mPAP and RW-mPAP relationships
and prior work as noted above. That is, because of the pressure-dependency of ZC, both ZC and compliance
decrease with HPH.
Our experimental approach enables us to differentiate between reactive (Rho kinase-dependent) and fixed (Rho
kinase-independent) changes induced by chronic hypoxia. While the approach is robust, these results may be
dependent on the species we chose, the duration of hypoxia, and even the strain of mouse. Indeed, significant
strain-dependent differences have been found in mouse lungs in response to chronic hypoxia (57), which may
complicate comparisons to transgenic and knockout strains on a non-C57BL6 background. In C57BL6 male mice
after 10 days of chronic hypoxia, we found evidence of fixed changes in the proximal vasculature and both
reactive and fixed changes in the distal vasculature. The fixed structural changes in the proximal vasculature

include stiffening of the proximal, conduit arteries, which is consistent with previous clinical (4, 23, 50) and
experimental studies (8, 26–28, 54). Evidence of reactive changes in the distal arteries includes the significant
drop in PAP and Z0 with administration of Y27632, which is supported by prior literature as noted above
(10, 19, 43); evidence of fixed changes include the apparent loss of small arteries in a Rho kinase-inhibited state
(Fig. 4) and the persistent difference in Z0 between CTL and HPH lungs in the Rho kinase-inhibited state.

Limitations.
We did not obtain PVZ results above 20 Hz, which is only twice the native heart rate of the mouse (52), because
the system cannot generate higher-frequency oscillations in flow sufficiently close to the desired magnitude (1
to 5 ml/min). We cannot exclude that additional information could be obtained at higher frequencies and that
our calculation of ZC would change if these were included. However, in vivo the lower harmonics contain the
most power and thus the most information (38). In addition, our calculations of impedance spectra are based on
pulsatile waveforms with single frequencies that were imposed in a fixed order. Time-dependent effects, such as
loss of drug efficacy or increased pulmonary vascular permeability, could therefore have affected our higherfrequency data more than our lower-frequency data. However, given the short duration of all pulsatile flow
trials (66 s in total for three sequential trials from f = 1 to 20 Hz), this effect is likely to be small.
In the isolated perfused lung system, because of the lower than physiological flow rate (by about 3-fold) and
perfusate viscosity (by 3- to 4-fold), mean PAP is lower than commonly reported in vivo in control and hypoxic
mice (10). Since, as we show here, ZC and RW are highly pressure dependent, this difference likely affects the
measured values of impedance metrics. Our use of a fixed airway pressure, at end-inspiration, while pressureflow measurements are obtained is also different from the in vivo condition. Thus, at this time, our results
cannot be compared with in vivo measurements of impedance.

Conclusion.
Our results demonstrate that acute administration of Y27632 has dramatic effects on small resistance arteries in
the pulmonary circulation. Our results also show that Y27632 has little or no direct effect on the large conduit
arteries that significantly impact RV afterload. These findings support the idea that fasudil decreases resistance
of small arteries with no change in the compliance of the large arteries, which may explain its lack of efficacy for
treatment of severe pulmonary hypertension.
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APPENDIX
In an artery with intramural pressure P and zero extramural pressure, the circumferential stress at a radial
distance r is given by
𝑟 2 [𝑟 2 +(𝑟i +ℎ)2]
[(𝑟i +ℎ)2 −𝑟i2 ]

𝜎(𝑟) = 𝑃 𝑟i2

(A1)

(16) where ri is the inner radius and h is the wall thickness such that ri ≤ r ≤ ri + h (Fig. A1). The stress at the
midwall radius rm is then
𝑟 2 [𝑟m2 +(𝑟i +ℎ)2 ]
2
2
m [(𝑟i +ℎ) −𝑟i ]

𝜎m = 𝑃 𝑟i2

(A2)

We introduce the midwall radius here because if we compute the midwall stress and strain referenced to the
no-load midwall radius, we can reasonably ignore the effects of residual stresses (65). The midwall strain (εm)
referenced to the no-load midwall radius (rm0) is
1

2

𝑟

𝜀m = 2 [(𝑟 m ) − 1] (A3)
m0

by Green's formulation assuming large deformations (ε∼1). Finally, the midwall stress and strain are related by
the elastic modulus E assuming a linearly elastic material where
𝜎m = 𝐸𝜀m (A4)
Substituting Eqs. A2 and A3 into Eq. A4, we obtain
𝑟 2 (𝑟m2 +(𝑟i +ℎ)2 )
2
2
m [(𝑟i +ℎ) −𝑟i ]

1

2

𝑟

= 𝐸 2 [(𝑟 m ) − 1] (A5)

𝑃 𝑟i2

m0

Exploiting the geometric relationship
𝑟i = 𝑟m − ℎ/2 (A6)
we obtain
𝑃

ℎ 2
2
𝑟m2

ℎ 2

[𝑟m2 +(𝑟m + 2) ]

(𝑟m − )

ℎ 2
ℎ 2
[(𝑟m + 2) −(𝑟m − 2) ]

1

2

𝑟

= 𝐸 2 [(𝑟 m ) − 1] (A7)
m0

which can be rewritten to yield
1

1

2𝑟m4 −ℎ𝑟m3 − ℎ 2 𝑟m2 + ℎ 4
4
16
2ℎ𝑟m3

=

𝐸
𝑟m 2
)
[(
2𝑃 𝑟m0

− 1] (A8)

Equation A8 can then be rearranged into a polynomial expression in rm
𝐸 ℎ𝑟

𝐸

1

1

(2 − 𝑃 𝑟2m ) 𝑟m4 + (𝑃 − 1) ℎ𝑟m3 − 4 ℎ2 𝑟m2 + 16 ℎ4 = 0 (A9)
m0

However, this equation implicitly depends on P, because h is a function of P, so we invoke conservation of mass
for the artery from the no-load state to the deformed state with no change in length as
ℎ 2

ℎ 2

𝜋 (𝑟m + 2 ) − 𝜋 (𝑟m − 2 ) = 𝜋 (𝑟m0 +

ℎ0 2
)
2

ℎ0 2
)
2

− 𝜋 (𝑟m0 −

(A10)

where h0 is the no-load wall thickness. This relationship can be more simply expressed
ℎ𝑟m = ℎ0 𝑟m0 (A11)
such that Eq. A9 can be rewritten with only explicit dependence on P
𝐸 ℎ

𝐸

1

1

ℎ0 𝑟m0 4
)
𝑟m

(2 − 𝑃 𝑟 0 ) 𝑟m4 + (𝑃 − 1) (ℎ0 𝑟m0 )𝑟m2 − 4 (ℎ0 𝑟m0 )2 + 16 (
m0

Or, more simply

= 0 (A12)

𝐸 ℎ

𝐸

1

1

(2 − 𝑃 𝑟 0 ) 𝑟m8 + (𝑃 − 1) (ℎ0 𝑟m0 )𝑟m6 − 4 (ℎ0 𝑟m0 )2 𝑟m4 + 16 (ℎ0 𝑟m0 )4 = 0 (A13)
m0

This polynomial expression can be solved explicitly for rm in terms of E, rm0, h0, and pressure P. Then, given rm, we
can solve for h and derive
ZC = √

𝜌𝐸ℎ
ℎ 5
2

2𝜋2 (𝑟𝑚 − )

(A14)

Fig. A1.Definitions of radial distance (r), inner radius (ri), wall thickness (h), outer radius (ri + h), and midwall
radius (rm) that are used to derive theoretical ZC-mPAP relationship.
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